eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Share:
Send email
Share:
Original paper

Impact of androgen deprivation therapy in patients with unfavorable intermediate-risk prostate cancer receiving brachytherapy-based dose-escalated radiation therapy

Nikhil T. Sebastian
1
,
Subir Goyal
2
,
Yuan Liu
2, 3
,
Vishal Dhere
1
,
Ashesh B. Jani
1
,
Bruce Hershatter
1
,
Pretesh R. Patel
1
,
Jay W. Shelton
1
,
Sheela Hanasoge
1
,
Karen D. Godette
1
,
Sagar A. Patel
1

  1. Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA
  2. Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA, USA
  3. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA
J Contemp Brachytherapy 2024; 16
DOI: https://doi.org/10.5114/jcb.2024.143130
Online publish date: 2024/09/20
Article files
- Impact of androgen.pdf  [0.22 MB]
- Impact of androgen - supplementary table.pdf  [0.05 MB]
Get citation
 
 
1. Burt LM, Shrieve DC, Tward JD. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Adv Radiat Oncol 2018; 3: 170-180.
2. Siegel RL, Miller KD, Wagle NS et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.
3. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-1239.
4. Krauss D, Kestin L, Ye H et al. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1064-1071.
5. Pasalic D, Kuban DA, Allen PK et al. Dose escalation for prostate adenocarcinoma: A long-term update on the outcomes of a phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys 2019; 104: 790-797.
6. Krauss DJ, Karrison T, Martinez AA et al. Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial. J Clin Oncol 2023; 41: 3203-3216.
7. Michalski JM, Winter KA, Prestidge BR et al. Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG Oncology RTOG 0232 randomized clinical trial. J Clin Oncol 2023; 41: 4035-4044.
8. Oh J, Tyldesley S, Pai H et al. An updated analysis of the survival endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys 2023; 115: 1061-1070.
9. Liu Y, Nickleach DC, Zhang C et al. Carrying out streamlined routine data analyses with reports for observational studies: introduction to a series of generic SAS (®) macros. F1000Res 2018; 7: 1955.
10. Schaeffer EM, Srinivas S, Adra N et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023; 21: 1067-1096.
11. Merrick GS, Galbreath RW, Butler WM et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 2007; 110: 289-296.
12. Ho AY, Burri RJ, Cesaretti JA et al. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 16-22.
13. Stock RG, Yalamanchi S, Hall SJ et al. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 2010; 183: 546-550.
14. Merrick GS, Wallner KE, Butler WM et al. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 2012; 82: e449-455.
15. Bittner N, Merrick GS, Butler WM et al. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic? Brachytherapy 2013; 12: 14-18.
16. Tran AT, Mandall P, Swindell R et al. Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. Radiother Oncol 2013; 109: 235-240.
17. Merrick GS, Wallner KE, Galbreath RW et al. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease? Brachytherapy 2016; 15: 79-84.
18. Nguyen PL, Alibhai SM, Basaria S et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67: 825-836.
19. Keyes M, Merrick G, Frank SJ et al. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy – a systematic literature review. Brachytherapy 2017; 16: 245-265.
20. Mohiuddin JJ, Narayan V, Venigalla S et al. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy 2019; 18: 322-331.
21. Jackson WC, Hartman HE, Dess RT et al. Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: A network meta-analysis of randomized trials. J Clin Oncol 2020; 38: 3024-3031.
22. Andruska N, Agabalogun T, Fischer-Valuck BW et al. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy. Brachytherapy 2022; 21: 617-625.
23. Andruska N, Fischer-Valuck BW, Carmona R, Agabalogun T, Brenneman RJ, Gay HA, et al. Outcomes of patients with unfavorable intermediate-risk prostate cancer treated with external-beam radiotherapy versus brachytherapy alone. J Natl Compr Canc Netw 2022; 20: 343-50.e4
24. Mendez LC, Martell K, Warner A et al. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. Radiother Oncol 2020; 150: 195-200.
25. Smile TD, Tom MC, Halima A et al. (125)I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. Brachytherapy 2022; 21: 85-93.
26. Spratt DE, Zhang J, Santiago-Jiménez M et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J Clin Oncol 2018; 36: 581-590.
27. Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-1216.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.